Halozyme Therapeutics Analyst Ratings
Halozyme Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/09/2023 | 60.99% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy |
| 09/08/2023 | 60.99% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy |
| 08/30/2023 | 60.99% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy |
| 08/15/2023 | 60.99% | HC Wainwright & Co. | $61 → $60 | Maintains | Buy |
| 08/10/2023 | 63.67% | Morgan Stanley | $60 → $61 | Maintains | Overweight |
| 07/24/2023 | 63.67% | HC Wainwright & Co. | → $61 | Initiates Coverage On | → Buy |
| 07/24/2023 | 20.74% | Goldman Sachs | $43 → $45 | Downgrades | Buy → Neutral |
| 05/10/2023 | 77.09% | JMP Securities | → $66 | Reiterates | → Market Outperform |
| 05/10/2023 | 60.99% | Morgan Stanley | $64 → $60 | Maintains | Overweight |
| 05/10/2023 | 23.42% | Piper Sandler | → $46 | Upgrades | Neutral → Overweight |
| 03/27/2023 | 55.62% | Berenberg | → $58 | Reinstates | → Buy |
| 03/17/2023 | 28.79% | Wells Fargo | $55 → $48 | Maintains | Overweight |
| 03/16/2023 | 12.69% | SVB Leerink | → $42 | Downgrades | Outperform → Market Perform |
| 03/16/2023 | 47.57% | Wells Fargo | $65 → $55 | Maintains | Overweight |
| 03/06/2023 | 71.72% | Morgan Stanley | $65 → $64 | Maintains | Overweight |
| 02/23/2023 | 39.52% | JP Morgan | $54 → $52 | Maintains | Overweight |
| 02/22/2023 | 77.09% | JMP Securities | $62 → $66 | Reiterates | → Market Outperform |
| 01/11/2023 | 63.67% | SVB Leerink | $62 → $61 | Maintains | Outperform |
| 12/21/2022 | 74.4% | Morgan Stanley | $53 → $65 | Maintains | Overweight |
| 12/08/2022 | 82.45% | Benchmark | $55 → $68 | Maintains | Buy |
| 11/28/2022 | 74.4% | Wells Fargo | → $65 | Initiates Coverage On | → Overweight |
| 11/22/2022 | 44.89% | JP Morgan | $53 → $54 | Maintains | Overweight |
| 11/14/2022 | 66.35% | SVB Leerink | $52 → $62 | Maintains | Outperform |
| 11/09/2022 | 66.35% | JMP Securities | $60 → $62 | Maintains | Market Outperform |
| 09/09/2022 | 34.16% | Morgan Stanley | → $50 | Initiates Coverage On | → Overweight |
| 05/26/2022 | 60.99% | Goldman Sachs | $48 → $60 | Maintains | Buy |
| 05/11/2022 | 55.62% | JMP Securities | $55 → $58 | Maintains | Market Outperform |
| 11/24/2021 | 55.62% | Wells Fargo | $60 → $58 | Maintains | Overweight |
| 11/03/2021 | 47.57% | JMP Securities | $52 → $55 | Maintains | Market Outperform |
| 11/03/2021 | 28.79% | SVB Leerink | $50 → $48 | Maintains | Outperform |
| 06/14/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 05/17/2021 | 50.25% | SVB Leerink | → $56 | Initiates Coverage On | → Outperform |
| 05/11/2021 | 28.79% | Piper Sandler | $50 → $48 | Downgrades | Overweight → Neutral |
| 12/17/2020 | 34.16% | Berenberg | → $50 | Initiates Coverage On | → Buy |
| 11/16/2020 | 60.99% | Wells Fargo | $39 → $60 | Maintains | Overweight |
| 07/02/2020 | -16.82% | Piper Sandler | $28 → $31 | Maintains | Overweight |
| 07/01/2020 | 4.64% | Benchmark | → $39 | Initiates Coverage On | → Buy |
| 06/15/2020 | -30.24% | Citigroup | $18 → $26 | Maintains | Neutral |
| 05/19/2020 | -27.56% | Canaccord Genuity | $23 → $27 | Maintains | Buy |
| 05/12/2020 | -8.77% | JMP Securities | $24 → $34 | Maintains | Market Outperform |
| 05/12/2020 | -38.29% | JP Morgan | $22 → $23 | Maintains | Overweight |
| 05/12/2020 | -6.09% | BMO Capital | $27 → $35 | Maintains | Outperform |
| 05/04/2020 | 4.64% | Cantor Fitzgerald | $35 → $39 | Reiterates | → Overweight |
| 02/25/2020 | -46.34% | Barclays | $16 → $20 | Maintains | Equal-Weight |
| 02/25/2020 | -40.97% | JP Morgan | $24 → $22 | Maintains | Overweight |
| 02/05/2020 | -27.56% | Piper Sandler | $18 → $27 | Upgrades | Neutral → Overweight |
| 01/27/2020 | -6.09% | Cantor Fitzgerald | $27 → $35 | Maintains | Overweight |
| 01/09/2020 | -35.61% | BMO Capital | $17 → $24 | Upgrades | Market Perform → Outperform |
| 01/08/2020 | -35.61% | Goldman Sachs | → $24 | Initiates Coverage On | → Buy |
| 11/20/2019 | -27.56% | Cantor Fitzgerald | $26 → $27 | Reiterates | → Overweight |
| 11/13/2019 | -54.39% | BMO Capital | $16 → $17 | Maintains | Market Perform |
| 11/13/2019 | -38.29% | JP Morgan | $20 → $23 | Maintains | Overweight |
| 11/05/2019 | -57.07% | Barclays | $17 → $16 | Upgrades | Underweight → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/09/2023 | 60.99% | HC Wainwright公司 | →$60 | 重申 | 購買→購買 |
| 09/08/2023 | 60.99% | HC Wainwright公司 | →$60 | 重申 | 購買→購買 |
| 2023年08月30日 | 60.99% | HC Wainwright公司 | →$60 | 重申 | 購買→購買 |
| 2023年08月15日 | 60.99% | HC Wainwright公司 | $61→$60 | 維護 | 買 |
| 2023年08月10日 | 63.67% | 摩根士丹利 | $60→$61 | 維護 | 超重 |
| 07/24/2023 | 63.67% | HC Wainwright公司 | →$61 | 開始承保 | →購買 |
| 07/24/2023 | 20.74% | 高盛 | $43→$45 | 評級下調 | 購買→中性 |
| 2023年05月10日 | 77.09% | JMP證券 | →$66 | 重申 | →市場跑贏大盤 |
| 2023年05月10日 | 60.99% | 摩根士丹利 | $64→$60 | 維護 | 超重 |
| 2023年05月10日 | 23.42% | 派珀·桑德勒 | →$46 | 升級 | 中性→超重 |
| 03/27/2023 | 55.62% | 貝倫伯格 | →$58 | 恢復 | →購買 |
| 03/17/2023 | 28.79% | 富國銀行 | $55→$48 | 維護 | 超重 |
| 03/16/2023 | 12.69% | SVB Leerink | →$42 | 評級下調 | 跑贏→市場表現 |
| 03/16/2023 | 47.57% | 富國銀行 | $65→$55 | 維護 | 超重 |
| 03/06/2023 | 71.72% | 摩根士丹利 | $65→$64 | 維護 | 超重 |
| 02/23/2023 | 39.52% | 摩根大通 | $54→$52 | 維護 | 超重 |
| 02/22/2023 | 77.09% | JMP證券 | $62→$66 | 重申 | →市場跑贏大盤 |
| 2023年1月11日 | 63.67% | SVB Leerink | $62→$61 | 維護 | 跑贏大盤 |
| 2022年12月21日 | 74.4% | 摩根士丹利 | $53→$65 | 維護 | 超重 |
| 12/08/2022 | 82.45% | 基準 | $55→$68 | 維護 | 買 |
| 2022年11月28日 | 74.4% | 富國銀行 | →$65 | 開始承保 | →超重 |
| 2022年11月22日 | 44.89% | 摩根大通 | $53→$54 | 維護 | 超重 |
| 2022年11月14日 | 66.35% | SVB Leerink | $52→$62 | 維護 | 跑贏大盤 |
| 11/09/2022 | 66.35% | JMP證券 | $60→$62 | 維護 | 市場表現強於大盤 |
| 09/09/2022 | 34.16% | 摩根士丹利 | →$50 | 開始承保 | →超重 |
| 2022年05月26日 | 60.99% | 高盛 | $48→$60 | 維護 | 買 |
| 2022年05月11日 | 55.62% | JMP證券 | $55→$58 | 維護 | 市場表現強於大盤 |
| 2021年11月24日 | 55.62% | 富國銀行 | $60→$58 | 維護 | 超重 |
| 11/03/2021 | 47.57% | JMP證券 | $52→$55 | 維護 | 市場表現強於大盤 |
| 11/03/2021 | 28.79% | SVB Leerink | $50→$48 | 維護 | 跑贏大盤 |
| 2021/06/14 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 2021/05/17 | 50.25% | SVB Leerink | →$56 | 開始承保 | →跑贏大盤 |
| 2021/11/05 | 28.79% | 派珀·桑德勒 | $50→$48 | 評級下調 | 超重→中性 |
| 12/17/2020 | 34.16% | 貝倫伯格 | →$50 | 開始承保 | →購買 |
| 11/16/2020 | 60.99% | 富國銀行 | $39→$60 | 維護 | 超重 |
| 07/02/2020 | -16.82% | 派珀·桑德勒 | $28→$31 | 維護 | 超重 |
| 07/01/2020 | 4.64% | 基準 | →$39 | 開始承保 | →購買 |
| 2020/06/15 | -30.24% | 花旗集團 | $18→$26 | 維護 | 中性 |
| 2020/05/19 | -27.56% | 卡納科特·格納奇 | $23→$27 | 維護 | 買 |
| 2020/05/12 | -8.77% | JMP證券 | $24→$34 | 維護 | 市場表現強於大盤 |
| 2020/05/12 | -38.29% | 摩根大通 | $22→$23 | 維護 | 超重 |
| 2020/05/12 | -6.09% | 蒙特利爾銀行資本 | $27→$35 | 維護 | 跑贏大盤 |
| 05/04/2020 | 4.64% | 康託·菲茨傑拉德 | $35→$39 | 重申 | →超重 |
| 02/25/2020 | -46.34% | 巴克萊 | $16→$20 | 維護 | 等重 |
| 02/25/2020 | -40.97% | 摩根大通 | $24→$22 | 維護 | 超重 |
| 02/05/2020 | -27.56% | 派珀·桑德勒 | $18→$27 | 升級 | 中性→超重 |
| 2020/01/27 | -6.09% | 康託·菲茨傑拉德 | $27→$35 | 維護 | 超重 |
| 1/09/2020 | -35.61% | 蒙特利爾銀行資本 | $17→$24 | 升級 | 市場表現優於→ |
| 1/08/2020 | -35.61% | 高盛 | →$24 | 開始承保 | →購買 |
| 2019年11月20日 | -27.56% | 康託·菲茨傑拉德 | $26→$27 | 重申 | →超重 |
| 2019年11月13日 | -54.39% | 蒙特利爾銀行資本 | $16→$17 | 維護 | 市場表現 |
| 2019年11月13日 | -38.29% | 摩根大通 | $20→$23 | 維護 | 超重 |
| 2019年11月05日 | -57.07% | 巴克萊 | $17→$16 | 升級 | 重量不足的→等重 |
What is the target price for Halozyme Therapeutics (HALO)?
Halozyme Treeutics(Halo)的目標價格是多少？
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by HC Wainwright & Co. on October 9, 2023. The analyst firm set a price target for $60.00 expecting HALO to rise to within 12 months (a possible 60.99% upside). 24 analyst firms have reported ratings in the last year.
HC Wainwright&Co.於2023年10月9日報道了Halozyme治療公司(納斯達克代碼：HALO)的最新目標價。這家分析公司將目標價定為60.00美元，預計Halo將在12個月內上漲(可能上漲60.99%)。去年有24家分析公司公佈了評級。
What is the most recent analyst rating for Halozyme Therapeutics (HALO)?
Halozyme Treateutics(Halo)的最新分析師評級是多少？
The latest analyst rating for Halozyme Therapeutics (NASDAQ: HALO) was provided by HC Wainwright & Co., and Halozyme Therapeutics reiterated their buy rating.
對Halozyme治療公司(納斯達克代碼：HALO)的最新分析師評級是由HC Wainwright&Co.提供的，Halozyme治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Halozyme Therapeutics (HALO)?
Halozyme治療公司(Halo)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on October 9, 2023 so you should expect the next rating to be made available sometime around October 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查看公共財務報表，與Halozyme治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Halozyme治療公司的上一次評級是在2023年10月9日提交的，所以你應該預計下一次評級將在2024年10月9日左右提供。
Is the Analyst Rating Halozyme Therapeutics (HALO) correct?
分析師對Halozyme Treeutics(Halo)的評級正確嗎？
While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a reiterated with a price target of $0.00 to $60.00. The current price Halozyme Therapeutics (HALO) is trading at is $37.27, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Halozyme治療公司(Halo)評級被重申，目標價在0.00美元到60.00美元之間。Halozyme治療公司(Halo)目前的交易價格為37.27美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。